Birmingham Platelet Group Unveils Pioneering Nanobody Technology Breakthrough
Researchers from the University of Birmingham have introduced a groundbreaking development in the realm of thrombosis research. They have pioneered a novel class of antibody fragments known as "nanobodies" to enhance our understanding of platelet disorders, such as bleeding and thrombosis. This innovation marks a significant milestone for thrombosis researchers, as it has enabled the creation of binding molecules with precisely defined compositions, capable of inducing predictable platelet clumping. Using nanobodies as reagents promises to advance our knowledge of platelet activation in laboratory settings.
Although nanobodies exhibit a short half-life within a living organism, this limitation can be addressed by conjugating them to larger inert molecules, potentially opening up new avenues for the development of therapeutics for blood and thrombotic disorders. Furthermore, nanobodies offer the potential for the establishment of validated clinical assays to diagnose patients with platelet disorders, including those related to bleeding and thrombosis. They also serve as invaluable tools for researchers investigating platelet activation.
Nanobodies share several characteristics with conventional antibodies, but they come with distinct advantages for platelet researchers. Their smaller size makes them well-suited for cross-linking, and their stability, combined with a high affinity for platelet receptors, makes them ideal reagents for receptor imaging. The research team at Birmingham has systematically designed nanobodies with different numbers of binding sites and examined their ability to generate signaling molecules and stimulate platelet activation.
